Syndax Pharmaceuticals Inc — Director's Dealing 2021

Oct 27, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Syndax Pharmaceuticals Inc (SNDX)
CIK: 0001395937
Period of Report: 2021-10-25

Reporting Person: Metzger Michael A (N/A)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-10-25	Common Stock	M	44704.00	$7.20	Acquired	62363.00	Direct
2021-10-25	Common Stock	S	44704.00	$19.1333	Disposed	17659.00	Direct
2021-10-26	Common Stock	M	16296.00	$7.20	Acquired	33955.00	Direct
2021-10-26	Common Stock	S	16296.00	$19.1964	Disposed	17659.00	Direct

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-10-25	Stock Options (Right to buy)	$7.20	M	44704.00	Disposed	2025-06-01	Common Stock (44704.00)	Direct
2021-10-26	Stock Options (Right to buy)	$7.20	M	16296.00	Disposed	2025-06-01	Common Stock (16296.00)	Direct

Footnotes

F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 plan adopted by the Reporting Person.

F2: The share price ranged from $19.00 to $19.48

F3: The sales price ranged from $19.01 to $19.33

F4: This option is fully vested.